US-based medical equipment firm Edwards Lifesciences has secured the European CE-Mark for the use of its self-expanding heart valve, Centera, in severe, symptomatic aortic stenosis patients who are at high risk of open-heart surgery.

Designed as a repositionable and retrievable device, Centera comes pre-attached to a 14-French, motorised delivery system.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The transcatheter aortic valve replacement (TAVR) option is intended to allow stable deployment and simplified approach.

Edwards Lifesciences transcatheter heart valves corporate vice-president Larry Wood said: “Edwards is committed to partnering with clinicians to offer differentiated, best-in-class technologies for transcatheter heart valve therapy.

“European certification of the Centera valve provides a meaningful treatment option for high-risk TAVR patients when their heart team recommends a self-expanding device.”

“The self-expanding valve was reported to have led to high survival rates of 99%, low rates of 2.5% disabling stroke, and 4.9% permanent pacemaker rate at 30 days.”

The European clearance is based on the data obtained from the multi-centre Centera-EU clinical trial performed in 203 high-risk patients at 23 sites across Europe, Australia, and New Zealand.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

When treated through the transfemoral access route, the self-expanding valve was reported to have led to high survival rates of 99%, low rates of 2.5% disabling stroke, and 4.9% permanent pacemaker rate at 30 days.

In addition, there was a low rate (around 0.6%) of moderate and no incidents of severe paravalvular leak. All the subjects in the trial were followed for a period of five years.

Edwards Lifesciences consultant Didier Tchétché said: “With the Edwards Centera valve, European clinicians and their patients may now benefit from a self-expanding TAVR option that has demonstrated exceptional clinical safety and performance outcomes in the high surgical risk population.”

Medical Device Network Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Medical Device Network Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving medical devices advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now